Enozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.

Journal:

Cancer Research

Published:

2025-11-06

DOI:

10.1158/0008-5472.can-25-3502

Affiliations:

11

Authors:

31

Go to article

Institutions	Authors	Share
ORIC Pharmaceuticals, United States of America (USA)	23.000000 23.000000 23.000000	0.74
Voronoi, South Korea	5.000000	0.16
Baylor College of Medicine (BCM), United States of America (USA)	1.000000	0.03
Paraza Pharma Inc., Canada	1.000000	0.03
Virginia Cancer Specialists (VCS), United States of America (USA)	1.000000	0.03

Interested in Oncology and Carcinogenesis?